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mated by initial low density lipoprotein (LDL) cholesterol
and the initial ratio of total cholesterol (TC) to high den-
sity lipoprotein (HDL) cholesterol.
RESULTS: Analyses will be conducted for each clinical pa-
rameter varying the parameters by appropriate amounts.
This will assess the robustness of the model and the impact
of key clinical parameters on baseline results. 
CONCLUSIONS: By separating behavioral factors from
treatment effect, the study will determine if clinical pa-
rameters play a major role in primary prevention of CHD
with cholesterol-lowering agents.
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OBJECTIVES: A study was undertaken to compare the
epidemiology and costs associated with primary preven-
tion of coronary heart disease (CHD) in males in France,
Germany, Italy, Spain, and the United Kingdom.
METHODS: Country-specific epidemiological and cost
data were collected as part of an economic evaluation of
CHD and analyzed for differences between countries. Ep-
idemiological and economic data were collected for men
in eight 5-year age groups (35–39 to 70–74 years). These
data were primarily obtained from the published litera-
ture and complemented by expert opinion.
RESULTS: Mean systolic blood pressure ranged from
125 to 132 for the 35–39 year olds and from 143.9 to
155.5 for the 70–74 year olds. Mean body mass index
ranged from 24.7 to 26.9 for the 35–39 year olds and
from 25.5 to 27.75 for the 70–74 year olds. The propor-
tion of smokers ranged from 0.38 to 0.56 for the 35–39
year olds and from 0.2 to 0.29 for the 70–74 year olds.
With adjustment by the respective health purchasing
power parities, direct costs of CHD ranged from £11,515
to £20,431 for acute myocardial infarction, £8,484 to
£17,898 for complicated angina, £606 to £10,227 for un-
complicated angina, and £305 to £9,734 for sudden and
nonsudden death. 
CONCLUSIONS: The epidemiological data showed simi-
lar trends within the five countries with some observed dif-
ferences for certain variables and/or age groups. Resource
utilization data differed significantly between countries—a
not surprising finding considering the profound differences
in healthcare systems and treatment patterns across Eu-
rope. In addition, differences in currency values and unit
costs make direct comparison of costs difficult.
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OBJECTIVE: We conducted a health economic and out-
comes study of post-menopausal women in Belgium to
quantify the benefits and risks associated with HRT. Us-
ing data provided by l’Université Catholique de Louvain,
the analysis was designed to predict the long-term clinical
and economic effects related to the conjugated estrogens/
medroxyprogesterone HRT (E/M HRT) regimen.
METHODS: Hypothetical cohorts of uterine-intact post-
menopausal women who were fully compliant with E/M
HRT were compared with similar cohorts of post-meno-
pausal women who did not use any form of HRT.
Markov cohort simulation analysis, guided by a Delphi
panel of local clinical and health economic experts, was
employed to model the short- and long-term implica-
tions of compliance with E/M HRT. Eight distinct health
states were considered in the analysis: healthy, osteo-
porosis, coronary heart disease, cerebrovascular disease,
Alzheimer’s Disease, breast cancer, colorectal cancer, and
death.
RESULTS: Results of this analysis suggest that patients
using E/M HRT therapy are expected to experience im-
proved health outcomes and an increased life expectancy
of more than 5 months per patient when compared those
not on HRT. These results are achieved with a modest
increase in cost of 8,415 BF, or 18,300 BF per life-year
gained.
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OBJECTIVE: To address willingness to pay (WTP) of pa-
tients with painful-irritable bladder syndrome (PIBS) us-
ing a regression model.
METHODS: A sample of 60 patients with PIBS from Se-
attle and Philadelphia were interviewed. The survey ques-
tionnaire contained a WTP question with 11 bids ranging
from $1 to $200. Two versions of the questionnaire were
administered, one for “improvement” of the condition
and one for “cure.” Respondents recorded whether they
would accept or reject each bid at the stated dollar value.
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Data about patients’ self-perceived severity, symptoma-
tology, and demographic variables such as education and
income were collected.
RESULTS: Results were analyzed with ordinary least
square regression (OLS). The dependent variable is maxi-
mum willingness to pay (WTP), which is defined as the
largest dollar value of the “yes, definitely” or “yes, prob-
ably” response to the bids. Independent variables in-
cluded income, education, self-perceived severity, symp-
tom bothersomeness, number of medical appointments
for their condition in the past year, and number of years
having the condition.
CONCLUSION: The OLS analysis produced a higher ex-
pected WTP for cure than for improvement. The R-square
and F statistics for each model showed that the variables
in the model strongly explain the variation of WTP at a
significant level. The regression results showed that edu-
cation and number of medical appointments in the past
year had a positive impact on willingness to pay for im-
provement, while education and self-perceived severity
demonstrated a positive impact on WTP for cure.
PGIU2
EVALUATING CLINICAL OUTCOMES OF
GERD TREATMENT OPTIONS USING
DECISION ANALYSIS
McGhan WF1, Smith MD2, Crawley JA3
1University of the Sciences at Philadelphia, Philadelphia, PA, US; 
2Health Decision Strategies, Princeton, NJ, US; 3Astra 
Pharmaceuticals, Wayne, PA, US
Long-term maintenance therapies with proton pump inhib-
itor (PPI), H2 receptor-antagonist (H2RA), or prokinetic
agents are often utilized in patients with symptoms of gas-
troesophageal reflux disease (GERD) or erosive esophagitis.
Maintenance therapy can be short-term symptomatic drug
treatment repeated when symptoms reoccur (intermittent)
or long-term continuous treatment (continuous).
OBJECTIVE: To assess which maintenance treatment re-
sults in the most asymptomatic patients, and for continu-
ous treatment, to assess if the dose should be reduced
(step-down therapy) or the patient switched to another
drug.
METHODS: A decision tree analytic model with a 1-year
time frame comparing clinical outcomes of maintenance
drug treatment options with omeprazole, ranitidine, or
cisapride was used. Healing rates used in the model were
determined by meta-analysis of randomized clinical stud-
ies. The decision tree was constructed based on published
treatment algorithms.
RESULTS: For continuous treatment: at 4 months, 94%
of patients taking omeprazole 20 mg daily were asymp-
tomatic vs 77% for ranitidine 300 mg daily. Stepping
down from omeprazole 20 mg to 10 mg resulted in 91%
asymptomatic, and switching to ranitidine 300 mg daily
resulted in 77% of patients asymptomatic; at 12 months,
99% of patients were asymptomatic for all continuous
treatment options. However, of these, 63% had no treat-
ment failures throughout the year for omeprazole 20 mg,
versus 51% for patients stepped down to omeprazole 10
mg daily, versus 32% for patients switched to ranitidine
300 mg daily, and versus 38% for patients taking raniti-
dine 300 mg daily initially. For intermittent treatment: at
12 months, 79%, 76%, and 80% of patients were asymp-
tomatic for omeprazole 20 mg, ranitidine 300 mg, and
cisapride 40 mg daily, respectively. 
CONCLUSIONS: Continuous maintenance treatment
options resulted in more patients asymptomatic than in-
termittent treatment options. Continuous treatment with
PPI resulted in more patients asymptomatic with fewer
treatment failures throughout the year vs H2RA, step-
down, or switch therapy.
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In the UK, certain anti-ulcer agents are used for prophy-
laxis against non-steroidal anti-inflammatory drug (NSAID)
toxicity.
OBJECTIVE: The objective of this study was to compare
the incidence of hospitalizations for gastrointestinal events
during exposure to these ulcer-healing drugs coprescribed
with NSAIDs.
METHODS: This was a population-based, observational,
record linkage study that included 427,786 patients regis-
tered with general practitioners in Tayside, Scotland be-
tween 1989 and 1994. Redeemed prescriptions for NSAIDs
and anti-ulcer drugs, and hospital discharge diagnoses of
patients to whom they were given, were obtained.
RESULTS: The risks of hospitalization for a gastrointes-
tinal event during concurrent exposure to NSAIDs and ei-
ther misoprostol or proton-pump inhibitors, adjusted for
recorded risk factors, were no greater than during expo-
sure to NSAIDs alone in patients with and without a
prior history of such events. By contrast, adjusted event
rates were twice as high during combined exposure to H2
receptor antagonist and NSAID compared with NSAIDs
alone in patients with a prior history (p  0.001), and
20% higher in patients without (p  0.001). Risks of
hospitalizations for gastroduodenal ulcers, erosions, gas-
tritis, and duodenitis during exposure to misoprostol were
23% less than those during exposure to H2 receptor an-
tagonists (p  0.001). No such difference was found with
proton-pump inhibitors. Despite the apparent greater ef-
ficacy of misoprostol and proton-pump inhibitors relative
to H2 receptor antagonists in patients with a prior his-
tory, their use was less common in these high-risk pa-
tients. 
CONCLUSIONS: The observed preferential use of H2
